Cardiovascular Diabetology

1. Cardiovasc Diabetol11 Nov 2026

   Diabetes mellitus and 10-year clinical outcomes after percutaneous coronary intervention with drug-eluting stents: insights from the DECADE cooperation

   Meta-analysisT2D & other

2. Cardiovasc Diabetol30 Sep 2026

   Cumulative estimated glucose disposal rate and longitudinal eGDR patterns in relation to incident cardiovascular disease among middle-aged and older adults with metabolic dysfunction-associated steatotic liver disease: a prospective cohort study

   Cohort studyLipids & liver

3. Cardiovasc Diabetol23 Sep 2026

   Antecedent, landmark, and two-visit cumulative triglyceride-glucose index and non-traditional lipid measures in relation to incident cardiovascular disease in adults with cardiovascular-kidney-metabolic syndrome (CKM) stages 0–3: a nationwide prospective cohort study

   Cohort studyLipids & liver

4. Cardiovasc Diabetol22 Sep 2026

   Mild autonomous cortisol secretion (MACS) is associated with increased mortality in patients with adrenal adenomas only in the presence of type 2 diabetes: a retrospective cohort study

   Cohort studyAdrenal

5. Cardiovasc Diabetol18 Sep 2026

   Subclinical cardiac involvement during diabetic ketoacidosis at type 1 diabetes onset in youth: biomarker elevation, altered diastolic filling, and reduced global longitudinal strain: a prospective cohort study

   Cohort study

6. Cardiovasc Diabetol11 Sep 2026

   Epigenetic and genetic factors modifying the association between diet quality and incident type 2 diabetes: the EPIC-Potsdam cohort

   Cohort studyT2D & other

7. Cardiovasc Diabetol9 Sep 2026

   Integrative plasma proteomic network analysis identifies physical activity-associated protein modules potentially mediating type 2 diabetes risk

   Cohort studyT2D & other

8. Cardiovasc Diabetol5 Sep 2026

   Rapid progression of coronary atherosclerosis across glycemic status: a serial coronary computed tomography angiography study from the PARADIGM registry

   Cohort studyT2D & other

9. Cardiovasc Diabetol3 Sep 2026

   Evaluative performance of triglyceride-glucose-frailty index versus surrogate insulin resistance indices for advanced cardiovascular-kidney-metabolic syndrome, cardiometabolic multimorbidity, and mortality: the role of estimated glomerular filtration rate

   Cohort study

10. Cardiovasc Diabetol26 Aug 2026

    Composite C-reactive protein-triglyceride-glucose adiposity indices and incident cardiovascular-liver-metabolic multimorbidity: a prospective cohort study

    Cohort studyLipids & liver

11. Cardiovasc Diabetol26 Aug 2026

    Reduced serum acetyl-L-carnitine is associated with hypertensive disorders in women with gestational diabetes mellitus: a multi-omics study

    Cohort studyDiabetes in pregnancy

12. Cardiovasc Diabetol24 Aug 2026

    Excess risk of cardiovascular disease and mortality after amputation in type 2 diabetes: a nationwide population study from the Swedish National Diabetes Register

    Cohort studyT2D & other

13. Cardiovasc Diabetol24 Aug 2026

    Triglyceride-glucose waist-to-height ratio in relation to prevalent and incident multimorbidity: cross-sectional and prospective evidence from four national studies

    Cross-sectional studyT2D & other

14. Cardiovasc Diabetol23 Aug 2026

    The cholesterol, high-density lipoprotein, and glucose index and its derived indices predict cardiometabolic multimorbidity development and progression in metabolic dysfunction-associated steatotic liver disease individuals: a prospective cohort study

    Cohort studyLipids & liver

15. Cardiovasc Diabetol9 Aug 2026

    C-reactive protein–triglyceride glucose index for the detection of the severity of coronary artery disease in different glucose metabolic states in patients with H-type hypertension

    Cohort studyComplications

16. Cardiovasc Diabetol7 Aug 2026

    A three-metabolite microbiota-associated signature for early risk stratification of gestational diabetes mellitus

    Case-control studyDiabetes in pregnancy

17. Cardiovasc Diabetol5 Aug 2026

    Predicting all-cause and cardiovascular mortality in hypertensive patients by combining the CHG index and its obesity indicators: a prospective cohort study with survival prediction model

    Cohort studyObesity

18. Cardiovasc Diabetol1 Aug 2026

    Lipids and apolipoproteins affect the risk of ST-elevation and non-ST-elevation myocardial infarctions differently in type 1 diabetes: a nationwide finnish cohort study

    Cohort studyT1D

19. Cardiovasc Diabetol30 Jul 2026

    Epicardial adipose tissue volume and nephropathy in people living with type 2 diabetes: the Kidn-EAT study

    Cross-sectional studyComplications

20. Cardiovasc Diabetol28 Jul 2026

    Effect of empagliflozin on copeptin levels in patients with recent acute coronary syndrome and newly detected dysglycaemia: a post-hoc analysis of the SOCOGAMI randomized controlled trial

    Secondary analysisT2D & other

21. Cardiovasc Diabetol27 Jul 2026

    Diabetic retinopathy enhances coronary artery calcium-based cardiovascular risk stratification in patients with type 2 diabetes: insights from the ACCoDiab study

    Cohort studyT2D & other

22. Cardiovasc Diabetol26 Jul 2026

    Proteomic signatures characterized by inflammatory signaling and metabolic processes have divergent associations with 30-year incidence of coronary artery disease in type 1 diabetes: the Pittsburgh Epidemiology of Diabetes Complications cohort

    Cohort studyT1D

23. Cardiovasc Diabetol26 Jul 2026

    Unraveling the dual role of fibroblast growth factor 5 (FGF5) in cardiorenal diseases through multi-omics causal inference

    Mechanistic study

24. Cardiovasc Diabetol26 Jul 2026

    Longitudinal inflammatory-metabolic-adiposity burden and incident heart failure across cardiovascular-kidney-metabolic stages: a prospective cohort study

    Cohort study

25. Cardiovasc Diabetol26 Jul 2026

    Association of the triglyceride-glucose index with subclinical left ventricular dysfunction in type 2 diabetes mellitus: mediation by myocardial energetic efficiency and resting perfusion

    Cross-sectional studyT2D & other

26. Cardiovasc Diabetol25 Jul 2026

    Association between insulin resistance–related indices and the risk of recurrence after catheter ablation in patients with nonvalvular atrial fibrillation

    Cohort study

27. Cardiovasc Diabetol25 Jul 2026

    Baseline, repeated-measure burden, and two-time-point patterns of the triglyceride-glucose index-visceral lipid ratio (TyG-VLR) and incident cardiovascular disease in cardiovascular-kidney-metabolic (CKM) syndrome stages 0–3: a longitudinal China Health and Retirement Longitudinal Study (CHARLS) analysis

    Cohort study

28. Cardiovasc Diabetol24 Jul 2026

    Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage

    Mechanistic studyT2D & other

29. Cardiovasc Diabetol23 Jul 2026

    Preclinical carotid atherosclerosis is independently associated with cardiovascular events and mortality in type 1 diabetes

    Cohort studyT1D

30. Cardiovasc Diabetol23 Jul 2026

    Associations between cardiac adipose tissue volume, measures of coronary calcification, myocardial microvascular function and systemic inflammation in individuals with type 2 diabetes free of overt cardiovascular disease

    Cross-sectional studyT2D & other

31. Cardiovasc Diabetol23 Jul 2026

    Post-translational modifications in the insoluble fraction of platelet-poor plasma distinguish pre-COVID-19 Postural Orthostatic Tachycardia Syndrome, Long COVID, and Long COVID-POTS: a preliminary study

    Cross-sectional study

32. Cardiovasc Diabetol22 Jul 2026

    Genetically proxied glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor pathway modulation is associated with favorable aging phenotypes: a drug-target Mendelian randomization study

    Research articleT2D & other

33. Cardiovasc Diabetol17 Jul 2026

    Associations of cumulative exposure and dynamic trajectories of the cholesterol–HDL–glucose index and its obesity-related derivatives with cardiovascular disease: a nationwide prospective cohort study

    Cohort studyObesity

34. Cardiovasc Diabetol17 Jul 2026

    Lipoprotein(a), insulin resistance, and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease

    Cohort studyLipids & liver

35. Cardiovasc Diabetol16 Jul 2026

    Association between the combined cholesterol, high-density lipoprotein, glucose index and frailty index and new-onset cardiovascular disease in individuals with cardiovascular-kidney-metabolic syndrome stages 0–3: evidence from CHARLS

    Cohort study

36. Cardiovasc Diabetol12 Jul 2026

    Multi-omics signatures of circulating factors associated with cardiorespiratory fitness adaptations in individuals with prediabetes

    Mechanistic studyT2D & other

37. Cardiovasc Diabetol12 Jul 2026

    Plasma proteomic profiling deciphers molecular dynamics linking insulin resistance to multiple chronic diseases and mortality

    Cohort study

38. Cardiovasc Diabetol12 Jul 2026

    Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study

    Cohort studyT2D & other

39. Cardiovasc Diabetol12 Jul 2026

    Sex- and menopause-specific inverse associations between metabolic dysfunction–associated steatotic liver disease and serum lipoprotein(a) concentrations: evidence from SHIP and UK Biobank

    Cross-sectional studyLipids & liver

40. Cardiovasc Diabetol11 Jul 2026

    Frailty may confound the association between MASLD and cardiovascular mortality in people with cardiometabolic risk factors

    Cohort studyLipids & liver

All 1,291 Briefs in ExploreShowing the 40 most recently published